A new mini review was published in Oncotarget’s Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.”
Pharma reputation slips among patient advocacy groups, according to annual survey
Patient advocacy groups’ perception of pharma companies fell for the first time since beginning a steady rise five years ago, a sign that the industry
April 30, 2024